Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
EMBC 
Embecta Corp (EMBC)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/03/2025: EMBC (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
5 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $16.67
1 Year Target Price $16.67
| 1 | Strong Buy |
| 0 | Buy |
| 3 | Hold |
| 1 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 18.2% | Avg. Invested days 32 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  2.0 |
| Profits based on simulation | Last Close 12/03/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 719.71M USD | Price to earnings Ratio 7.55 | 1Y Target Price 16.67 |
Price to earnings Ratio 7.55 | 1Y Target Price 16.67 | ||
Volume (30-day avg) 5 | Beta 1.06 | 52 Weeks Range 9.10 - 20.50 | Updated Date 12/3/2025 |
52 Weeks Range 9.10 - 20.50 | Updated Date 12/3/2025 | ||
Dividends yield (FY) 4.90% | Basic EPS (TTM) 1.63 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-11-25 | When - | Estimate 0.46 | Actual 0.5 |
Profitability
Profit Margin 8.83% | Operating Margin (TTM) 24.85% |
Management Effectiveness
Return on Assets (TTM) 16.59% | Return on Equity (TTM) - |
Valuation
Trailing PE 7.55 | Forward PE - | Enterprise Value 1921582302 | Price to Sales(TTM) 0.67 |
Enterprise Value 1921582302 | Price to Sales(TTM) 0.67 | ||
Enterprise Value to Revenue 1.78 | Enterprise Value to EBITDA 6.76 | Shares Outstanding 58512841 | Shares Floating 57267103 |
Shares Outstanding 58512841 | Shares Floating 57267103 | ||
Percent Insiders 0.47 | Percent Institutions 100.57 |
Upturn AI SWOT
Embecta Corp
Company Overview
History and Background
Embecta Corp. was spun off from Becton, Dickinson and Company (BD) in April 2022, becoming an independent, publicly traded company focused solely on diabetes care. Its history is intertwined with BD's long history in medical technology.
Core Business Areas
- Insulin Delivery: Develops and sells pen needles and syringes for insulin injection used in diabetes management.
Leadership and Structure
Embecta Corp. is led by a CEO and an executive management team. The organizational structure reflects its focus on manufacturing and distributing diabetes care products.
Top Products and Market Share
Key Offerings
- Pen Needles: Embecta's pen needles are used with insulin pens for subcutaneous insulin delivery. Market share data is difficult to pinpoint exactly, but Embecta is a leading provider. Competitors include Novo Nordisk, B. Braun, and Owen Mumford.
- Syringes: Embecta's insulin syringes are used for insulin delivery. Market share data is difficult to pinpoint exactly, but Embecta is a leading provider. Competitors include B. Braun, and Cardinal Health.
Market Dynamics
Industry Overview
The diabetes care market is driven by the increasing prevalence of diabetes worldwide. This is supported by an aging population and lifestyle changes. The market includes insulin delivery devices, blood glucose monitoring systems, and diabetes medications.
Positioning
Embecta focuses on insulin delivery segment. The company competes on the product's price and quality.
Total Addressable Market (TAM)
The global diabetes market size was valued at USD 92.77 billion in 2023 and is projected to grow from USD 98.99 billion in 2024 to USD 157.82 billion by 2032. Embecta addresses the insulin delivery portion of this TAM.
Upturn SWOT Analysis
Strengths
- Dedicated focus on diabetes care
- Established brand reputation from BD legacy
- Established manufacturing and distribution capabilities
- High product quality
Weaknesses
- Concentrated product portfolio
- Dependence on insulin manufacturers
- Spin-off risks and transition challenges
Opportunities
- Expanding into emerging markets
- Developing new insulin delivery technologies
- Acquiring complementary businesses
- Partnering with diabetes technology companies
Threats
- Competition from established medical device companies
- Price pressures from healthcare payers
- Technological advancements (e.g., insulin pumps)
- Changing regulatory landscape
Competitors and Market Share
Key Competitors
- NVO
- BDX
- OHI
Competitive Landscape
Embecta holds a strong position in insulin delivery. It faces competition from larger, more diversified medical device companies that also operate in the diabetes space. Embecta's competitive advantage relies on its specialization and legacy brand recognition.
Growth Trajectory and Initiatives
Historical Growth: Historical Growth data is not available here as it can vary significantly. Please refer to Embecta Corp's investor relations page for the most up-to-date information.
Future Projections: Future Projections data is not available here as it can vary significantly. Please refer to Embecta Corp's investor relations page for the most up-to-date information.
Recent Initiatives: Recent strategic initiatives include the continued optimization of operations and focus on insulin delivery.
Summary
Embecta Corp, as a focused diabetes care company spun off from Becton Dickinson, faces opportunities in the growing diabetes market but also inherent spin-off challenges. Its core business in insulin delivery gives it a solid foundation. Embecta must navigate competition from larger players and changing technological landscapes. The company should focus on efficient operations to succeed.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company filings
- Industry reports
- Market research reports
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. Market data and projections are subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Embecta Corp
Exchange NASDAQ | Headquaters Parsippany, NJ, United States | ||
IPO Launch date 2022-04-01 | President, CEO & Director Mr. Devdatt Kurdikar Ph.D. | ||
Sector Healthcare | Industry Medical Instruments & Supplies | Full time employees 1850 | Website https://www.embecta.com |
Full time employees 1850 | Website https://www.embecta.com | ||
Embecta Corp., a medical device company, provides solutions to improve the health and wellbeing of people living with diabetes in the United States and internationally. The company's products include pen needles, syringes, and safety injection devices, as well as digital applications to assist people with managing patient's diabetes. It primarily sells its products to wholesalers and distributors. The company was formerly known as Berra Newco, Inc. Embecta Corp. was founded in 1924 and is headquartered in Parsippany, New Jersey.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.